Achiko AG (ACHKF) Stock
Achiko AG, established in 2018 and based in Zurich, Switzerland, focuses on pioneering diagnostic technologies for both Indonesian and international markets. Its flagship innovation is AptameX, a rapid diagnostic test that identifies the SARS-CoV-2 virus by utilizing DNA aptamers, distinguishing it from traditional antigen-based methods.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Achiko AG
Achiko AG, established in 2018 and based in Zurich, Switzerland, focuses on pioneering diagnostic technologies for both Indonesian and international markets. Its flagship innovation is AptameX, a rapid diagnostic test that identifies the SARS-CoV-2 virus by utilizing DNA aptamers, distinguishing it from traditional antigen-based methods. The company also offers Teman Sehat, a mobile application serving as a check-in and digital health passport. Additionally, under the Mimopay brand, Achiko AG provides secure payment processing, enabling game publishers and application developers to accept diverse payment methods for digital content and merchandise. The firm is also involved in the development of game software.
Achiko AG (ACHKF) stock trades at $0.00 with a market capitalization of $377400. The stock is valued at a price-to-earnings (P/E) ratio of -0.04, price-to-book of -0.08, price-to-sales of 6.04. Over the past 52 weeks the stock has ranged between $0.00 and $0.00, and currently trades —% below its 52-week high.
On profitability, Achiko AG generates a return on equity (ROE) of 180.00% — well above the market average, a sign of a high-quality business, return on capital employed of 378.29%.
Official website: www.achiko.com